HOME / ¹®¼°øÀ¯ / ºñÁî´Ï½º / ±âŸ/ÀϹÝ
5.0
1°ÇÀÇ Èı⺸±â±¹Á¦Çмú´ëȸ ¹ßÇ¥µÈ Á¾ÇÕº´¿ø °ËÁø ÇÁ·Î±×·¥°ú ¹ÌÁúº´¿¹¹æ À§¿øȸÀÇ ±Ç°í¾È Æò°¡º¸°í¼ Âü°íÀÚ·áÀÔ´Ï´Ù.
º» ¹®¼ÀÇ ºÐ·® : 55 ÆäÀÌÁö |
1Àå Challenges for prevention
2Àå Evidence-based medicine
3Àå Why be strict when evidence is insufficient?
4Àå Where US medicine fails EBM
5Àå The U.S. Preventive Services Task Force
6Àå Steps in explicit process (USPSTF)
7Àå Evidence grading
8Àå Analytic framework
9Àå Analytic framework for screening for a disease
10Àå Grades of Recommendation
11Àå Wording of recommendations
12Àå The I letter grade
13Àå Reasons for conflicting recommendations
14Àå Conflicting guidelines
15Àå Other areas of uncertainty
16Àå Summary of task force method
17Àå Differences from USPSTF
18Àå Stomach cancer
19Àå Liver cancer
20Àå Multiphasic testing
21Àå Urine testing
22Àå Tumor marker testing
23Àå Imaging screening
24Àå Miscellaneous screening
25Àå Risks of screening (examples)
26Àå Conclusions
evaluating the nhic screening program, the general hospital health program, and the us preventive services task force recommendations: what does the evidence support?
ned calonge, m. d
, m. p
h. colorado chief medical officer chair, uspstf
°Ç°º¸Çè°ø´Ü°ú Á¾ÇÕº´¿øÀÇ °Ç°°ËÁøÇÁ·Î±×·¥ ¹×
¹Ì Áúº´¿¹¹æƯº°À§¿øȸ ±Ç°í¾È°úÀÇ ºñ±³ Æò°¡ :
±× °á°ú, ¿ì¸®´Â ¹«¾ùÀ» ¾Ë ¼ö Àִ°¡?
objectives(°ÀÇ ³»¿ë) discuss(³íÀÇ)
us preventive services task force structure, methods and recommendations
(¹Ì Áúº´¿¹¹æƯº°À§¿øȸÀÇ ±¸Á¶, ¹æ¹ý·Ð ¹× ±Ç°í»çÇ×)
evaluation of nhic screening program (±¹¹Î°Ç°º¸Çè°ø´ÜÀÇ °Ç°°ËÁø ÇÁ·Î±×·¥ Æò°¡) evaluation of general hospital health program (ÀÏ¹Ý Á¾ÇÕº´¿øÀÇ °Ç°°ËÁø ÇÁ·Î±×·¥ Æò°¡) challenges for prevention (¿¹¹æ»ç¾÷ÀÌ Á÷¸éÇÑ °úÁ¦) not everything that might work does work (¸ðµç °ÍÀÌ ´Ù ÀǵµµÈ °á°ú¸¦ °¡Á®¿ÀÁö´Â ¾ÊÀ½)
services should be supported by good evidence before they are widely recommended
(¿¹¹æ»ç¾÷Àº ³Î¸® ±Ç°íµÇ±â ÀÌÀü¿¡ ÃæºÐÇÑ ±Ù°Å¿¡ ÀÇÇØ µÞ¹Þħ µÇ¾î¾ß ÇÔ)
there are harms associated with screening that must be weighed against potential benefit, especially if benefit is unproven
(ƯÈ÷, °ËÁø½Ç½ÃÀÇ À¯ÀÍÇÔÀÌ ÀÔÁõµÇÁö ¾Ê´Â °æ¿ì¿¡´Â, ¹Ýµå½Ã °ËÁø¿¡ µû¸¥ ÀÌÀÍ°ú ÇؾÇÀÌ ºñ±³ °ËÅäµÈ ÈÄ °ËÁøÀ» ½Ç½Ã ÇÏ¿©¾ß ÇÔ)
evidence-based medicine (°úÇÐÀû Áõ°Å¿¡ ±âÃÊÇÑ ÀÇ·á)
base decisions on evidence of effectiveness and benefit
(ÀÔÁõµÈ È¿°ú¼º°ú À¯ÀÍÇÔÀ» ±âÃÊ·Î ÇÏ¿© °áÁ¤À» ³»·Á¶ó)
when there is evidence of benefit, do it (À¯ÀÍÇÔÀÌ ÀÖ´Ù´Â Áõ°Å°¡ ÀÖÀ¸¸é ½ÃÇàÇ϶ó)
when there is evidence of no benefit or harm, don¡¯t do it
(À̷οî Á¡ÀÌ ¾ø°Å³ª, Çطοî Á¡ÀÌ ÀÖ´Ù´Â Áõ°Å°¡ ÀÖÀ¸¸é ½ÃÇàÇÏÁö ¸»¾Æ¶ó)
when there is insufficient evidence to determine if there is benefit, be conservative: use individual discretion, but if there are harms or costs, don¡¯t do it
(ÀÌÁ¡ÀÌ ÀÖ´ÂÁö ¾ø´ÂÁö °áÁ¤ÇÒ ¼ö ÀÖ´Â Áõ°Å°¡ ÃæºÐÄ¡ ¾ÊÀ¸¸é, ½ÅÁßÇ϶ó : Àç·®À» ¹ßÈÖÇϵÇ, ÇØ°¡ Àְųª ºñ¿ëÀÌ ¸¹ÀÌ µé¸é ½ÃÇàÇÏÁö ¸»¾Æ¶ó)
why be strict when evidence is insufficient?
(ºÒÃæºÐÇÑ Áõ°Å ¼ö¿ë¿¡ µÚµû¸£´Â À§Ç輺) (ÀÌÇÏ »ý·«)
¹ÞÀº º°Á¡
5.0/5
1°³ÀÇ º°Á¡
¹®¼°øÀ¯ ÀڷḦ µî·ÏÇØ ÁÖ¼¼¿ä.
¹®¼°øÀ¯ Æ÷ÀÎÆ®¿Í Çö±ÝÀ» µå¸³´Ï´Ù.
Æ÷ÀÎÆ® : ÀÚ·á 1°Ç´ç ÃÖ´ë 5,000P Áö±Þ
Çö±Ý : ÀÚ·á 1°Ç´ç ÃÖ´ë 2,000¿ø Áö±Þ